{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:36:04Z","timestamp":1788914164700,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30998-z","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:19:00Z","timestamp":1764818340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In vitro anticancer studies of new derivatives based on the furanocoumarin scaffold"],"prefix":"10.1038","volume":"16","author":[{"given":"Wioletta","family":"Olejarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Augustynowicz-Kope\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"G\u0142ogowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Napi\u00f3rkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Szostek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Szulczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"30998_CR1","unstructured":"World Health Organization. Global cancer burden growing amidst mounting need for services. WHO. (2024). Available from: https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services"},{"key":"30998_CR2","unstructured":"American Cancer Society. Cancer Facts & Figs. 2024. ACS. (2024). Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2024-cancer-facts-figures.html"},{"issue":"3","key":"30998_CR3","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman, G. et al. Drug resistance in cancer: an overview. Cancers (Basel). 6 (3), 1769\u20131792. https:\/\/doi.org\/10.3390\/cancers6031769 (2014). PMID: 25198391; PMCID: PMC4190567.","journal-title":"Cancers (Basel)"},{"key":"30998_CR4","doi-asserted-by":"publisher","unstructured":"Gottesman, M. M. Mechanisms of Cancer Drug Resistance. Annual Review of Medicine, 53(Volume 53, 2002), 615\u2013627. https:\/\/doi.org\/https:\/\/doi.org\/ (2002). https:\/\/doi.org\/10.1146\/annurev.med.53.082901.103929","DOI":"10.1146\/annurev.med.53.082901.103929"},{"issue":"6","key":"30998_CR5","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","volume":"121","author":"RA Ward","year":"2021","unstructured":"Ward, R. A. et al. Challenges and opportunities in cancer drug resistance. Chem. Rev. 121 (6), 3297\u20133351. https:\/\/doi.org\/10.1021\/acs.chemrev.0c00383 (2021).","journal-title":"Chem. Rev."},{"key":"30998_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246203","author":"ST Asma","year":"2022","unstructured":"Asma, S. T. et al. Natural Products\/Bioactive Compounds as a Source of Anticancer Drugs. Cancers https:\/\/doi.org\/10.3390\/cancers14246203 (2022).","journal-title":"Cancers"},{"issue":"17","key":"30998_CR7","doi-asserted-by":"publisher","first-page":"24411","DOI":"10.1007\/s11356-021-17795-7","volume":"29","author":"MI Khan","year":"2022","unstructured":"Khan, M. I. et al. Anticancer properties of medicinal plants and their bioactive compounds against breast cancer: a review on recent investigations. Environ. Sci. Pollut. Res. 29 (17), 24411\u201324444. https:\/\/doi.org\/10.1007\/s11356-021-17795-7 (2022).","journal-title":"Environ. Sci. Pollut. Res."},{"issue":"1","key":"30998_CR8","doi-asserted-by":"publisher","first-page":"1429869","DOI":"10.1155\/2022\/1429869","volume":"2022","author":"M Yuan","year":"2022","unstructured":"Yuan, M. et al. The role of bioactive compounds in natural products extracted from plants in cancer treatment and their mechanisms related to anticancer effects. Oxidative Med. Cell. Longev. 2022 (1), 1429869. https:\/\/doi.org\/10.1155\/2022\/1429869 (2022).","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"2","key":"30998_CR9","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s11033-019-04620-1","volume":"46","author":"F Aydo\u011fmu\u015f-\u00d6zt\u00fcrk","year":"2019","unstructured":"Aydo\u011fmu\u015f-\u00d6zt\u00fcrk, F., Jahan, H., Beyazit, N., G\u00fcnayd\u0131n, K. & Choudhary, M. I. The anticancer activity of visnagin, isolated from Ammi Visnaga L., against the human malignant melanoma cell lines, HT 144. Mol. Biol. Rep. 46 (2), 1709\u20131714. https:\/\/doi.org\/10.1007\/s11033-019-04620-1 (2019).","journal-title":"Mol. Biol. Rep."},{"issue":"8","key":"30998_CR10","doi-asserted-by":"publisher","first-page":"8553","DOI":"10.1021\/acsomega.8b01088","volume":"3","author":"R Sharma","year":"2018","unstructured":"Sharma, R. et al. Khellinoflavanone, a semisynthetic derivative of Khellin, overcomes Benzo[a]pyrene toxicity in human normal and cancer cells that express CYP1A1. ACS Omega. 3 (8), 8553\u20138566. https:\/\/doi.org\/10.1021\/acsomega.8b01088 (2018).","journal-title":"ACS Omega"},{"key":"30998_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ejmech.2014.06.007","volume":"82","author":"FA Ragab","year":"2014","unstructured":"Ragab, F. A., Yahya, T. A. A., El-Naa, M. M. & Arafa, R. K. Design, synthesis and structure\u2013activity relationship of novel semi-synthetic flavonoids as antiproliferative agents. Eur. J. Med. Chem. 82, 506\u2013520. https:\/\/doi.org\/10.1016\/j.ejmech.2014.06.007 (2014).","journal-title":"Eur. J. Med. Chem."},{"issue":"32","key":"30998_CR12","doi-asserted-by":"publisher","first-page":"25312","DOI":"10.1039\/C4RA16228E","volume":"5","author":"OM Abdelhafez","year":"2015","unstructured":"Abdelhafez, O. M., Ali, H. I., Amin, K. M., Abdalla, M. M. & Ahmed, E. Y. Design, synthesis and anticancer activity of Furochromone and Benzofuran derivatives targeting VEGFR-2 tyrosine kinase. RSC Adv. 5 (32), 25312\u201325324. https:\/\/doi.org\/10.1039\/C4RA16228E (2015).","journal-title":"RSC Adv."},{"key":"30998_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bioorg.2017.12.029","volume":"76","author":"KM Amin","year":"2018","unstructured":"Amin, K. M. et al. Synthesis and molecular Docking study of new Benzofuran and furo[3,2-g]chromone-based cytotoxic agents against breast cancer and p38\u03b1 MAP kinase inhibitors. Bioorg. Chem. 76, 487\u2013500. https:\/\/doi.org\/10.1016\/j.bioorg.2017.12.029 (2018).","journal-title":"Bioorg. Chem."},{"issue":"7","key":"30998_CR14","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.bmc.2019.02.027","volume":"27","author":"OM Abdelhafez","year":"2019","unstructured":"Abdelhafez, O. M. et al. Design and molecular modeling of novel P38\u03b1 MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds. Bioorg. Med. Chem. 27 (7), 1308\u20131319. https:\/\/doi.org\/10.1016\/j.bmc.2019.02.027 (2019).","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"30998_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/apt.13302","volume":"42","author":"E Montassier","year":"2015","unstructured":"Montassier, E. et al. Chemotherapy-driven dysbiosis in the intestinal Microbiome. Aliment. Pharmacol. Ther. 42 (5), 515\u2013528. https:\/\/doi.org\/10.1111\/apt.13302 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"30998_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa, L. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29 (6), 1437\u20131444. https:\/\/doi.org\/10.1093\/annonc\/mdy103 (2018).","journal-title":"Ann. Oncol."},{"issue":"6371","key":"30998_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut Microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science 359 (6371), 97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236 (2018).","journal-title":"Science"},{"key":"30998_CR18","first-page":"77","volume":"61","author":"J Kossakowski","year":"1987","unstructured":"Kossakowski, J. & Zawadowski, T. SYNTHESIS OF AMINOALKANOL AND AMINOETHYL DERIVATIVES OF 4,9-DIHYDROXY-7-ETHYL-5H-FURO[3,2-g][1]BENZOPYRAN-5-ONE. Pol. J. Chem. 61, 77\u201383 (1987).","journal-title":"Pol. J. Chem."},{"issue":"6","key":"30998_CR19","first-page":"539","volume":"43","author":"J Kossakowski","year":"1986","unstructured":"Kossakowski, J. & Zawadowski, T. Synthesis of 4-(3-amino-2-hydroxypropoxy)furobenzopyrans. Acta Pol. Pharm. 43 (6), 539\u2013542 (1986).","journal-title":"Acta Pol. Pharm."},{"issue":"1","key":"30998_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41420-022-01207-x","volume":"8","author":"EV Sazonova","year":"2022","unstructured":"Sazonova, E. V., Chesnokov, M. S., Zhivotovsky, B. & Kopeina, G. S. Drug toxicity assessment: cell proliferation versus cell death. Cell. Death Discovery. 8 (1), 417. https:\/\/doi.org\/10.1038\/s41420-022-01207-x (2022).","journal-title":"Cell. Death Discovery"},{"issue":"1","key":"30998_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0022-1759(88)90310-9","volume":"115","author":"T Decker","year":"1988","unstructured":"Decker, T. & Lohmann-Matthes, M. L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods. 115 (1), 61\u201369. https:\/\/doi.org\/10.1016\/0022-1759(88)90310-9 (1988).","journal-title":"J. Immunol. Methods"},{"key":"30998_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221838","author":"M Mustafa","year":"2024","unstructured":"Mustafa, M. et al. Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications. Cells https:\/\/doi.org\/10.3390\/cells13221838 (2024).","journal-title":"Cells"},{"key":"30998_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejmech.2017.11.031","volume":"143","author":"G Huang","year":"2018","unstructured":"Huang, G. et al. Synthesis and biological evaluation of sulfur-containing Shikonin oxime derivatives as potential antineoplastic agents. Eur. J. Med. Chem. 143, 166\u2013181. https:\/\/doi.org\/10.1016\/j.ejmech.2017.11.031 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"30998_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejmech.2019.01.005","volume":"165","author":"G Huang","year":"2019","unstructured":"Huang, G. et al. Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents. Eur. J. Med. Chem. 165, 160\u2013171. https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.005 (2019).","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"30998_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1021\/acs.molpharmaceut.8b01062","volume":"16","author":"J Cui","year":"2019","unstructured":"Cui, J. et al. DMAKO-20 as a new multitarget anticancer prodrug activated by the tumor specific CYP1B1 enzyme. Mol. Pharm. 16 (1), 409\u2013421. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b01062 (2019).","journal-title":"Mol. Pharm."},{"issue":"3","key":"30998_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano, T. IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 33 (3), 127\u2013148. https:\/\/doi.org\/10.1093\/intimm\/dxaa078 (2021).","journal-title":"Int. Immunol."},{"issue":"4","key":"30998_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd.2016.253","volume":"16","author":"A Ashkenazi","year":"2017","unstructured":"Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat. Rev. Drug Discovery. 16 (4), 273\u2013284. https:\/\/doi.org\/10.1038\/nrd.2016.253 (2017).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"30998_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini, E., Maroni, G., del Re, M. & Tenen, D. G. EGFR signaling pathway as therapeutic target in human cancers. Sem. Cancer Biol. 85, 253\u2013275. https:\/\/doi.org\/10.1016\/j.semcancer.2022.04.002 (2022).","journal-title":"Sem. Cancer Biol."},{"issue":"3","key":"30998_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/13543776.2021.1860210","volume":"31","author":"X Sun","year":"2021","unstructured":"Sun, X., Shan, X., Zunhua, Y., Pengwu, Z., Zhu, W. & and Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). Expert Opin. Ther. Pat. 31 (3), 223\u2013238. https:\/\/doi.org\/10.1080\/13543776.2021.1860210 (2021).","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"30998_CR30","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","volume":"10","author":"RW Birkinshaw","year":"2019","unstructured":"Birkinshaw, R. W. et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat. Commun. 10 (1), 2385. https:\/\/doi.org\/10.1038\/s41467-019-10363-1 (2019).","journal-title":"Nat. Commun."},{"issue":"7042","key":"30998_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (7042), 677\u2013681. https:\/\/doi.org\/10.1038\/nature03579 (2005).","journal-title":"Nature"},{"issue":"9","key":"30998_CR32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/sj.cdd.4402178","volume":"14","author":"EF Lee","year":"2007","unstructured":"Lee, E. F. et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell. Death Differ. 14 (9), 1711\u20131713. https:\/\/doi.org\/10.1038\/sj.cdd.4402178 (2007).","journal-title":"Cell. Death Differ."},{"key":"30998_CR33","doi-asserted-by":"publisher","unstructured":"Hargreaves, D. et al. Design of rigid protein\u2013protein interaction inhibitors enables targeting of undruggable Mcl-1. Proceedings of the National Academy of Sciences, 120(21), e2221967120. (2023). https:\/\/doi.org\/10.1073\/pnas.2221967120","DOI":"10.1073\/pnas.2221967120"},{"key":"30998_CR34","doi-asserted-by":"publisher","unstructured":"Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Epidermal growth factor receptor tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib (2002). https:\/\/doi.org\/10.2210\/pdb1M17\/pdb","DOI":"10.2210\/pdb1M17\/pdb"},{"key":"30998_CR35","doi-asserted-by":"publisher","unstructured":"Yun, C. H. et al. Crystal structure of EGFR kinase domain G719S mutation in complex with Iressa (2006). https:\/\/doi.org\/10.2210\/pdb2ITO\/pdb","DOI":"10.2210\/pdb2ITO\/pdb"},{"key":"30998_CR36","doi-asserted-by":"publisher","unstructured":"Gajiwala, K. S. et al. Crystal structure of the wild-type EGFR kinase domain in complex with Dacomitinib (soaked) (2012). https:\/\/doi.org\/10.2210\/pdb4I23\/pdb","DOI":"10.2210\/pdb4I23\/pdb"},{"key":"30998_CR37","doi-asserted-by":"publisher","unstructured":"Yun, C. H. & Eck, M. J. EGFR L858R in complex with PD168393 (2013). https:\/\/doi.org\/10.2210\/pdb4LQM\/pdb","DOI":"10.2210\/pdb4LQM\/pdb"},{"key":"30998_CR38","doi-asserted-by":"publisher","unstructured":"Hargreaves, D., Studies, Reversible & EGFR C797S Triple Mutant Inhibitor Series. Towards a (2020). https:\/\/doi.org\/10.2210\/pdb7AEM\/pdb","DOI":"10.2210\/pdb7AEM\/pdb"},{"issue":"11","key":"30998_CR39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"DB Kitchen","year":"2004","unstructured":"Kitchen, D. B., Decornez, H., Furr, J. R. & Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discovery. 3 (11), 935\u2013949. https:\/\/doi.org\/10.1038\/nrd1549 (2004).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"7","key":"30998_CR40","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1136\/gutjnl-2021-326264","volume":"71","author":"NL Ting","year":"2022","unstructured":"Ting, N. L., Lau, H. C. & Yu, J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut 71 (7), 1412\u20131425. https:\/\/doi.org\/10.1136\/gutjnl-2021-326264 (2022).","journal-title":"Gut"},{"key":"30998_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.1.235","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res., 28(1), 235\u2013242. https:\/\/doi.org\/10.1093\/nar\/28.1.235 (2000)."},{"issue":"1","key":"30998_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/ct300857j","volume":"9","author":"P Eastman","year":"2013","unstructured":"Eastman, P. et al. OpenMM 4: A reusable, extensible, hardware independent library for high performance molecular simulation. J. Chem. Theory Comput. 9 (1), 461\u2013469. https:\/\/doi.org\/10.1021\/ct300857j (2013).","journal-title":"J. Chem. Theory Comput."},{"issue":"16","key":"30998_CR43","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated Docking with selective receptor flexibility. J. Comput. Chem. 30 (16), 2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256 (2009).","journal-title":"J. Comput. Chem."},{"key":"30998_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle, N. M. et al. Open babel: an open chemical toolbox. J. Cheminform. 3, 33. https:\/\/doi.org\/10.1186\/1758-2946-3-33 (2011).","journal-title":"J. Cheminform."},{"issue":"2","key":"30998_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock vina: improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 (2), 455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"issue":"8","key":"30998_CR46","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/ci300604z","volume":"53","author":"DR Koes","year":"2013","unstructured":"Koes, D. R., Baumgartner, M. P. & Camacho, C. J. Lessons learned in empirical scoring with Smina from the CSAR 2011 benchmarking exercise. J. Chem. Inf. Model. 53 (8), 1893\u20131904. https:\/\/doi.org\/10.1021\/ci300604z (2013).","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"30998_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12551-016-0247-1","volume":"9","author":"NS Pagadala","year":"2017","unstructured":"Pagadala, N. S. et al. Software for molecular docking: a review. Biophys. Rev. 9 (2), 91\u2013102. https:\/\/doi.org\/10.1007\/s12551-016-0247-1 (2017).","journal-title":"Biophys. Rev."},{"key":"30998_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv315","author":"S Salentin","year":"2015","unstructured":"Salentin, S. et al. PLIP: fully automated protein\u2013ligand interaction profiler. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkv315 (2015).","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"30998_CR49","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/bioinformatics\/btu829","volume":"31","author":"N Rego","year":"2015","unstructured":"Rego, N. & Koes, D. 3Dmol.js: molecular visualization with WebGL. Bioinformatics 31 (8), 1322\u20131324. https:\/\/doi.org\/10.1093\/bioinformatics\/btu829 (2015).","journal-title":"Bioinformatics"},{"key":"30998_CR50","unstructured":"BIOVIA & Syst\u00e8mes, D. Discovery Studio Visualizer, Version 20.1.0.19295 (Dassault Syst\u00e8mes, 2020)."},{"key":"30998_CR51","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ejmech.2018.07.041","volume":"156","author":"D Szulczyk","year":"2018","unstructured":"Szulczyk, D. et al. Design and synthesis of novel 1H-tetrazol-5-amine based potent antimicrobial agents: DNA topoisomerase IV and gyrase affinity evaluation supported by molecular Docking studies. Eur. J. Med. Chem. 156, 631\u2013640. https:\/\/doi.org\/10.1016\/j.ejmech.2018.07.041 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"30998_CR52","unstructured":"Woods, G. L. et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes [Internet]. 2nd edition. Wayne (PA): Clinical and Laboratory Standards Institute; 2011 Mar. (CLSI publication \/ Clinical and Laboratory Standards Institute, No. 31.5.) Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544374\/"},{"key":"30998_CR53","doi-asserted-by":"publisher","unstructured":"Franzblau, S. G. et al. Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay. J. Clin. Microbiology. 3654, 362\u2013366. https:\/\/doi.org\/10.1128\/JCM.36.2.362-366 (1998).","DOI":"10.1128\/JCM.36.2.362-366"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30998-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30998-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30998-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:03:03Z","timestamp":1768327383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30998-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30998"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30998-z","relation":{"references":[{"id-type":"doi","id":"10.1093\/nar\/28.1.235","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"W.O.: Manuscript review and editing, Anticancer studies, Supervision. E.A.K.: Antitubercular studies, Supervision. A.G.: Antitubercular studies, Data interpretation. M.N.: Synthesis, Data interpretation, Manuscript review and editing: T.S.: In silico studies, Molecular docking. A.F.: Anticancer studies, Data collection. D.S.: Conceptualization, Data collection and interpretation, Original manuscript writing, Supervision.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contribution"}},{"value":"Supplementary data for this article can be found online.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Supplementary Information"}}],"article-number":"1412"}}